|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size 2/28/19 Ekso Bionics Holdings, Inc. 10-K 12/31/18 107:8.7M |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 893K
2: EX-10.36 Material Contract HTML 62K
3: EX-21.1 Subsidiaries List HTML 27K
4: EX-23.1 Consent of Experts or Counsel HTML 29K
5: EX-31.1 Certification -- §302 - SOA'02 HTML 35K
6: EX-31.2 Certification -- §302 - SOA'02 HTML 35K
7: EX-32.1 Certification -- §906 - SOA'02 HTML 30K
8: EX-32.2 Certification -- §906 - SOA'02 HTML 30K
15: R1 Document And Entity Information HTML 64K
16: R2 Consolidated Balance Sheets HTML 113K
17: R3 Consolidated Balance Sheets (Parenthetical) HTML 50K
18: R4 Consolidated Statements of Operations and HTML 84K
Comprehensive Loss
19: R5 Consolidated Statements of Stockholders' Equity HTML 89K
20: R6 Consolidated Statements of Stockholders' Equity HTML 36K
(Parenthetical)
21: R7 Consolidated Statement of Cash Flows HTML 137K
22: R8 Organization HTML 40K
23: R9 Summary of Significant Accounting Policies and HTML 92K
Estimates
24: R10 Net Loss Per Share of Common Stock HTML 55K
25: R11 Intangible Assets HTML 47K
26: R12 Fair Value Measurements HTML 84K
27: R13 Revenue Recognition HTML 77K
28: R14 Property and Equipment, net HTML 53K
29: R15 Accrued Liabilities HTML 56K
30: R16 Long-Term Debt HTML 47K
31: R17 Lease Obligations HTML 42K
32: R18 Employee Benefit Plan HTML 33K
33: R19 Related Party Transactions HTML 35K
34: R20 Capitalization and Equity Structure HTML 103K
35: R21 Stock-based Compensation HTML 125K
36: R22 Income Taxes HTML 90K
37: R23 Contingencies and Commitments HTML 53K
38: R24 Segment Disclosures HTML 66K
39: R25 Subsequent events HTML 36K
40: R26 Summary of Significant Accounting Policies and HTML 134K
Estimates (Policies)
41: R27 Summary of Significant Accounting Policies and HTML 49K
Estimates (Tables)
42: R28 Net Loss Per Share of Common Stock (Tables) HTML 58K
43: R29 Intangible Assets (Tables) HTML 43K
44: R30 Fair Value Measurements (Tables) HTML 76K
45: R31 Revenue Recognition (Tables) HTML 68K
46: R32 Property and Equipment, net (Tables) HTML 51K
47: R33 Accrued Liabilities (Tables) HTML 56K
48: R34 Long-Term Debt (Tables) HTML 38K
49: R35 Lease Obligations table (Tables) HTML 37K
50: R36 Capitalization and Equity Structure (Tables) HTML 72K
51: R37 Stock-based Compensation (Tables) HTML 121K
52: R38 Income Taxes (Tables) HTML 84K
53: R39 Contingencies and Commitments (Tables) HTML 46K
54: R40 Segment Disclosures (Tables) HTML 69K
55: R41 Organization (Details) HTML 42K
56: R42 Summary of Significant Accounting Policies and HTML 36K
Estimates - AOCI (Details)
57: R43 Summary of Significant Accounting Policies and HTML 46K
Estimates - Narrative (Details)
58: R44 Summary of Significant Accounting Policies and HTML 44K
Estimates - Inventory (Details)
59: R45 Net Loss Per Share of Common Stock - Schedule of HTML 53K
EPS (Details)
60: R46 Net Loss Per Share of Common Stock - Antidilutive HTML 38K
Share (Details)
61: R47 Intangible Assets - Narrative (Details) HTML 41K
62: R48 Intangible Assets - Acquired Assets (Details) HTML 46K
63: R49 Fair Value Measurements - Fair Value Assets and HTML 47K
Liabilities (Details)
64: R50 Fair Value Measurements - Changes in Level 3 HTML 46K
(Details)
65: R51 Fair Value Measurements - Additional Information HTML 39K
(Details)
66: R52 Revenue Recognition - Deferred Revenue (Details) HTML 47K
67: R53 Revenue Recognition - Deferred Revenue Activity HTML 36K
(Details)
68: R54 Revenue Recognition - Additional Information HTML 48K
(Details)
69: R55 Revenue Recognition - Accounts Receivable HTML 37K
(Details)
70: R56 Revenue Recognition - Disaggregation of Revenue HTML 60K
(Details)
71: R57 Property and Equipment, net - Schedule of HTML 72K
Property, Plant and Equipment (Details)
72: R58 Property and Equipment, net - Narrative (Details) HTML 30K
73: R59 Accrued Liabilities - Schedule of Liabilities HTML 47K
(Details)
74: R60 Accrued Liabilities - Warranty Costs (Details) HTML 39K
75: R61 Long-Term Debt - Narrative (Details) HTML 56K
76: R62 Long-Term Debt - Debt Maturity (Details) HTML 52K
77: R63 Lease Obligations - Narrative (Details) HTML 65K
78: R64 Employee Benefit Plan (Details) HTML 34K
79: R65 Related Party Transactions (Details) HTML 45K
80: R66 Capitalization and Equity Structure - Additional HTML 53K
Information (Details)
81: R67 Capitalization and Equity Structure - 2017 HTML 100K
Offerings (Details)
82: R68 Capitalization and Equity Structure - Warrant HTML 72K
Share Activity (Details)
83: R69 Capitalization and Equity Structure - Fair Values HTML 44K
of Warrant Liability (Details)
84: R70 Capitalization and Equity Structure - 2014 PPO and HTML 48K
Merger Warrants and Pre-Merger Warrants (Details)
85: R71 Stock-based Compensation - 2014 Equity Incentive HTML 42K
Plan (Details)
86: R72 Stock-based Compensation - Shares Available for HTML 38K
Future Grant (Details)
87: R73 Stock-based Compensation - Stock Option Narrative HTML 37K
(Details)
88: R74 Stock-based Compensation - Summary of Stock Option HTML 84K
Activity (Details)
89: R75 Stock-based Compensation - Stock Options HTML 62K
Outstanding (Details)
90: R76 Stock-based Compensation - Exercised Options HTML 46K
Narrative (Details)
91: R77 Stock-based Compensation - Stock Option HTML 47K
Assumptions (Details)
92: R78 Stock-based Compensation - RSU Activity (Details) HTML 56K
93: R79 Stock-based Compensation - Compensation Expense HTML 41K
(Details)
94: R80 Stock-based Compensation - Employee Stock Purchase HTML 37K
Plan (Details)
95: R81 Income Taxes - Component of Income (Loss) Before HTML 35K
Income Taxes (Details)
96: R82 Income Taxes - Income Tax Expense (Benefit) HTML 58K
(Details)
97: R83 Income Taxes - Deferred Tax Assets and Liabilities HTML 57K
(Details)
98: R84 Income Taxes - Narrative (Details) HTML 48K
99: R85 Income Taxes - Unrecognized Tax Benefits (Details) HTML 36K
100: R86 Contingencies and Commitments - Narrative HTML 41K
(Details)
101: R87 Contingencies and Commitments - Contractual HTML 41K
Obligations (Details)
102: R88 Segment Disclosures - Segment Reporting HTML 48K
Information (Details)
103: R89 Segment Disclosures - Geographic Revenue HTML 36K
Information (Details)
104: R90 Subsequent events (Details) HTML 64K
106: XML IDEA XML File -- Filing Summary XML 191K
105: EXCEL IDEA Workbook of Financial Reports XLSX 110K
9: EX-101.INS XBRL Instance -- ekso-20181231 XML 2.26M
11: EX-101.CAL XBRL Calculations -- ekso-20181231_cal XML 259K
12: EX-101.DEF XBRL Definitions -- ekso-20181231_def XML 785K
13: EX-101.LAB XBRL Labels -- ekso-20181231_lab XML 2.01M
14: EX-101.PRE XBRL Presentations -- ekso-20181231_pre XML 1.22M
10: EX-101.SCH XBRL Schema -- ekso-20181231 XSD 213K
107: ZIP XBRL Zipped Folder -- 0001549084-19-000002-xbrl Zip 268K
| Exhibit |
(1) | I have reviewed this annual report on Form 10-K of Ekso Bionics Holdings, Inc.; |
(2) | Based
on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
(3) | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report; |
(4) | The
company’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have: |
(a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
(b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
(c) | Evaluated the effectiveness of the
company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
(d) | Disclosed in this report any change in the company’s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company’s internal control over financial reporting; and |
(5) | The
company’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company’s auditors and the audit committee of the company’s board of directors (or persons performing the equivalent functions): |
(a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company’s ability to record, process,
summarize and report financial information; and |
(b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the company’s internal control over financial reporting. |
/s/ John
F. Glenn |
Principal Financial Officer |
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 2/28/19 | 8-K | ||
| For Period end: | 12/31/18 | 11-K | ||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/24/22 Ekso Bionics Holdings, Inc. 10-K 12/31/21 103:9.4M 2/25/21 Ekso Bionics Holdings, Inc. 10-K 12/31/20 106:9.8M 2/25/21 Ekso Bionics Holdings, Inc. S-8 2/25/21 3:64K Toppan Merrill/FA 2/25/21 Ekso Bionics Holdings, Inc. S-8 2/25/21 3:64K Toppan Merrill/FA |